METHODS FOR DETERMINING EFFICACY OF ADALIMUMAB IN SUBJECTS HAVING ANKYLOSING SPONDYLITIS USING CTX-II AND MMP3 AS BIOMARKERS

摘要

The invention provides a method for determining the efficacy of a TNF± inhibitor, such as a TNF± antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.